trending Market Intelligence /marketintelligence/en/news-insights/trending/w4jak4wmd1nzojt2egxm1g2 content esgSubNav
In This List

Sirtex shareholders approve China Grand Pharmaceutical, CDH takeover

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Sirtex shareholders approve China Grand Pharmaceutical, CDH takeover

Sirtex Medical Ltd.'s shareholders voted in favor of a A$33.60-per-share takeover by China Grand Pharmaceutical and Healthcare Holdings Ltd. and CDH Investments.

The Australian biotechnology company is being acquired under a scheme of arrangement which has received clearance from the Australian Foreign Investment Review Board and the U.S. Federal Trade Commission.

Hong Kong-based China Grand Pharmaceuticals' shareholders have also approved the acquisition. CDH and CGP's offer implies an A$1.9 billion market capitalization for Sirtex.

On June 14, Sirtex recommended the takeover bid to its shareholders — months after agreeing to be acquired by California's Varian Medical Systems Inc. for A$28 per share. Sirtex has since paid a break fee of about A$15.8 million for backing out of that deal.